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Abstract
Purpose: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that afflicts about 4-12% of
women of reproductive age. First discovered by Stein and Leventhal in 1935, it is currently defined by the
National Institute of Health as oligo- or anovulation with features of hyperandrogenism, when all other
possible causes of menstrual irregularity and hyperandrogenism have been ruled out. PCOS can be distressing
to women due to infertility issues and hyperandrogenism symptoms. PCOS can be challenging to diagnose by
clinicians, and even more difficult to manage due to the large amount of presentations and treatment options.
Currently there is no standard or universal course of therapy available.
Methods: An exhaustive literature search using the following search engines: Medline, NEJM, PudMed and
CINAHL was conducted. Articles related to the topic but published more than 10 years ago were excluded.
Results: PCOS therapy should be appropriate for each patient taking into consideration her fertility, health
and cosmetic desires. All PCOS patients should first be treated with lifestyle changes as this can yield
improvement in all areas of pathogenesis. Diet, exercise and weight loss has proved efficacious in restoring
ovulation, improving hyperandrogenism and decreasing insulin resistance. Management of anovulation and
infertility will depend on whether or not the patient is attempting to conceive. If not, then oral contraceptives
to decrease the risk of endometrial carcinoma will be the appropriate choice. If the individual is trying to
conceive, then clomiphene citrate is considered first line in order to restore ovulation and promote fertility. If
the patient is clomiphene resistant then, metformin should be tried as it has shown to improve ovulation
although not as well as clomiphene. The next options include laparoscopic ovarian diathermy or gonadotropin
therapy. When treating symptoms of hyperandrogenism such as: hirsutism, acne, seborrhea and male pattern
baldness, anti-androgens should be used in all patients not attempting to conceive in order to reduce the
amount of systemic testosterone causing the symptoms. Specifically, hirsutism is generally treated with
mechanical methods. Metformin has also been shown to help improve hirsutism. Acne can be treated with
topical and oral antibiotics and seborrhea can be managed with steroid creams. Rogaine should be used in
women with male pattern baldness. Finally, and most importantly, women with PCOS should always be
screened and treated for insulin resistance and syndrome X to prevent and slow the progression of diabetic
and cardiovascular complications. If insulin resistance is found, patients should be put on metformin or TZDs
to increase insulin sensitization. Also, if other disorders associated with metabolic syndrome are present, such
as hyperlipidemia or hypertension, they should be treated appropriately.
Conclusion: If women with PCOS are diagnosed and managed properly with lifestyle changes and other
pharmacological and surgical therapy, most distressing symptoms can be alleviated and future complications
of diabetes and cardiovascular events can be slowed or prevented.
Degree Type
Capstone Project
Degree Name
Master of Science in Physician Assistant Studies
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/181
First Advisor
Mark Pedemonte, M.D.
Second Advisor
Jonathon W Gietzen MS PA-C
Keywords
Polycystic Ovarian Syndrome, PCOS, Stein-Leventhal Syndrome, Ovary, Polycystic
Subject Categories
Medicine and Health Sciences
Rights
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0
License.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/181
Copyright and terms of use
If you have downloaded this document directly from the web or from CommonKnowledge, see the
“Rights” section on the previous page for the terms of use.
If you have received this document through an interlibrary loan/document delivery service, the
following terms of use apply:
Copyright in this work is held by the author(s). You may download or print any portion of this document
for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). Except for personal
or fair use, you or your borrowing library may not reproduce, remix, republish, post, transmit, or
distribute this document, or any portion thereof, without the permission of the copyright owner. [Note:
If this document is licensed under a Creative Commons license (see “Rights” on the previous page)
which allows broader usage rights, your use is governed by the terms of that license.]
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge Rights,
Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. Email inquiries
may be directed to:. copyright@pacificu.edu
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/181
 
 
NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author(s) of this 
work have made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author(s) nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author(s) and advisor(s) disclaim all responsibility for the results 
obtained from use of the information contained in this work.  Knowledge and practice 
change constantly, and readers are advised to confirm the information found in this work 
with other more current and/or comprehensive sources. 
 
The student authors attest that this work is completely their original authorship and that 
no material in this work has been plagiarized, fabricated or incorrectly attributed.         
 
  
 
 
 
 
Diagnosis and Management of Polycystic Ovary Syndrome: A 
Literature Review 
 
 
 
 
 
 
By: 
 
 
 
 
 
Brandy Cannon 
 
 
 
 
 
 
 
 
 
 
A Clinical Research Project Submitted to the Faculty of the  
School of Physician Assistant Studies 
Pacific University, Forest Grove, OR  
For the Masters of Science Degree August, 2008 
 
Faculty Advisor: Mark Pedemonte, M.D.  
Clinical Project Advisor: Jonathon W Gietzen MS PA-C 
 
 
 
  1 
  
        
 
 
        
 
STATEMENT OF ACCEPTANCE: 
 
 
This project is hereby accepted as a requirement for completion of the degree of: 
Masters of Science in Physician Assistant Studies at Pacific University School of Physician Assistant 
Studies on this day the sixteenth of August, 2008. 
 
 
 
 
Brandy Cannon, PA-S     Date 
Author 
 
 
Jonathon W Gietzen MS, PA-C                Date 
Clinical Project Coordinator 
 
 
H. F. Randolph III, PA-C, MPAS      Date 
Program Director 
 
School of Physician Assistant Studies 
         
222 SE 8th Ave, Suite 551, Hillsboro, OR 97123 
                  
(503) 352-7272  E-Mail: pa@pacificu.edu 
 
  2 
Biography 
 
Brandy Cannon is a native of Washington State where she attended the University of Washington in 
Seattle.  After earning her B.S. in cellular biology, she moved back home to the town of Camas, WA 
where she worked as a CNA while taking a few prerequisite courses to prepare for PA school.  She 
gained acceptance into Pacific University’s Physician Assistant Program in 2006, but made the 
decision to stay in Washington and commute during her training.  During her clinical year she has 
gained interest in family practice and urgent care.  Brandy is married and the mother of two boys; ages 
5 years and 6mo old.  Her interests include camping, sports and family activities.  She plans to stay in 
Washington and work in Primary Care after graduation. 
 
 
 
  3 
Abstract   
 
Purpose: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that afflicts about 4-
12% of women of reproductive age.  First discovered by Stein and Leventhal in 1935, it is currently 
defined by the National Institute of Health as oligo- or anovulation with features of hyperandrogenism, 
when all other possible causes of menstrual irregularity and hyperandrogenism have been ruled out.  
PCOS can be distressing to women due to infertility issues and hyperandrogenism symptoms.  PCOS 
can be challenging to diagnose by clinicians, and even more difficult to manage due to the large 
amount of presentations and treatment options.  Currently there is no standard or universal course of 
therapy available. 
 
Methods: An exhaustive literature search using the following search engines: Medline, NEJM, 
PudMed and CINAHL was conducted.  Articles related to the topic but published more than 10 years 
ago were excluded.    
 
Results: PCOS therapy should be appropriate for each patient taking into consideration her fertility, 
health and cosmetic desires.  All PCOS patients should first be treated with lifestyle changes as this 
can yield improvement in all areas of pathogenesis.  Diet, exercise and weight loss has proved 
efficacious in restoring ovulation, improving hyperandrogenism and decreasing insulin resistance.  
Management of anovulation and infertility will depend on whether or not the patient is attempting to 
conceive.  If not, then oral contraceptives to decrease the risk of endometrial carcinoma will be the 
appropriate choice.  If the individual is trying to conceive, then clomiphene citrate is considered first 
line in order to restore ovulation and promote fertility.  If the patient is clomiphene resistant then, 
metformin should be tried as it has shown to improve ovulation although not as well as clomiphene.  
The next options include laparoscopic ovarian diathermy or gonadotropin therapy.   When treating 
symptoms of hyperandrogenism such as: hirsutism, acne, seborrhea and male pattern baldness, anti-
androgens should be used in all patients not attempting to conceive in order to reduce the amount of 
systemic testosterone causing the symptoms.  Specifically, hirsutism is generally treated with 
mechanical methods.  Metformin has also been shown to help improve hirsutism.  Acne can be treated 
with topical and oral antibiotics and seborrhea can be managed with steroid creams.  Rogaine should 
be used in women with male pattern baldness.  Finally, and most importantly, women with PCOS 
should always be screened and treated for insulin resistance and syndrome X to prevent and slow the 
progression of diabetic and cardiovascular complications.  If insulin resistance is found, patients 
should be put on metformin or TZDs to increase insulin sensitization.  Also, if other disorders 
associated with metabolic syndrome are present, such as hyperlipidemia or hypertension, they should 
be treated appropriately.   
 
Conclusion: If women with PCOS are diagnosed and managed properly with lifestyle changes and 
other pharmacological and surgical therapy, most distressing symptoms can be alleviated and future 
complications of diabetes and cardiovascular events can be slowed or prevented.      
 
Keywords:  Polycystic Ovarian Syndrome, PCOS, Stein-Leventhal Syndrome, Ovary, Polycystic, 
Management, Treatment, Therapy, Diagnosis. 
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 Diagnosis and Management of Polycystic Ovary Syndrome: A Literature Review 
 
INTRODUCTION 
 
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that afflicts about 4-12% of 
women of reproductive age.1  The disorder was first noted by Stein and Leventhal in 1935 when the 
link between amenorrhea, hirsutism, infertility and ovarian cysts was discovered.  Despite much debate 
in defining this disorder, most clinicians use the definition set forth by the National Institutes of Health 
in 1990.  Their diagnostic criteria included: oligo- or anovulation with features of hyperandrogenism, 
when all other possible causes of menstrual irregularity and hyperandrogenism have been ruled out.2,3  
Some investigators have included the presence of polycystic ovaries in this definition, while others 
classify this finding as nonspecific.2,4 
 The etiology of PCOS is unclear, but 3 hypotheses have been suggested by the Polycystic 
Ovary Syndrome Writing Committee (Table I).5  Although the specific cause is unknown, much of the 
symptoms of PCOS stem from hyperandrogenism and insulin resistance.4  Disorders linked to insulin 
resistance include increased risk for Metabolic Syndrome or Syndrome X.  The characteristics of this 
disorder include: central obesity with a waist circumference greater than 88cm, elevated triglycerides 
over 150 mg/dL, an HDL-C below 50 mg/dL, Hypertension, over 130/85 mmHg, and impaired fasting 
glucose higher than 110 mg/dL.  Having Metabolic Syndrome puts women at a much higher risk of 
cardiovascular complications and type 2 diabetes.1,4  Conditions associated with hyperandrogenism 
include hirsutism, which is excessive hair growth in women in a normally male pattern,6 acne, male 
pattern baldness, oligo- or anovulation, menstrual irregularity and infertility.4 
 PCOS can be challenging to diagnose, and even more difficult to manage due to the large 
amount of presentations and treatment options.  Currently there is no standard or universal course of 
therapy available.  The treatment for each patient must be tailored to each individual and the 
importance she places on certain symptoms and signs.  Another challenge is continuing to adjust 
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treatment in the face of changing symptoms.1  This paper will present the diagnosis and management 
options for PCOS.  Diagnostic criteria should include oligo- or anovulation with symptoms of 
hyperandrogenism, while other causes of both should be ruled out initially.2  Therapy should be 
targeted at controlling distressing symptoms for the patient such as those caused by hyperandrogenism, 
managing ovulation and infertility to allow patient to have children if desired and to prevent 
endometrial cancer, and finally, managing the long term effects of insulin resistance to prevent future 
cardiovascular and diabetic complications.1,4 
Methods 
An exhaustive literature search using the following search engines: Medline, NEJM, PudMed and 
CINAHL was conducted.  The following search terms were used: Polycystic Ovarian Syndrome, 
PCOS, Stein-Leventhal Syndrome, Ovary, Polycystic, Management, Treatment, Therapy, Lifestyle 
change, Infertility, Insulin Resistance, and Hyperandrogenism.  Articles related to the topic but 
published more than 10 years ago were excluded.  
Results
Diagnosis and Laboratory Evaluation 
Women with PCOS may have varied presentations including infertility, irregular menses, excess 
hair growth, etc or signs may be discovered during a routine physical exam including acanthosis 
nigricans, hirsutism, obesity, etc.  An in depth history should be taken paying special attention to 
menstrual and pregnancy history, medication use, social history including diet, smoking and 
alcohol use, and family history of cardiovascular disease and diabetes.1, 4  Unfortunately, there is 
no specific study or laboratory test that is diagnostic for PCOS so the clinician must rely on his 
knowledge of the signs and symptoms of the disease (Table II) to begin the proper workup for 
the disorder.1 
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 PCOS laboratory evaluation should seek positive labs that confirm the diagnosis while 
other disorders causing similar symptoms must be ruled out.  Hypothyroidism, 
Hyperprolactinemia, pregnancy and Cushings Syndrome can mimic the presentation of PCOS.  
Also, adrenal, ovarian, and stomach tumors can cause similar findings.  Other less common 
causes include acromegaly, late onset congenital adrenal hyperplasia, hyperthecosis, primary 
hypothalamic amenorrhea, and primary ovarian failure.  The corresponding laboratory tests and 
studies should be done and any abnormal values should be followed-up properly (Table III).  
Also, in an attempt to confirm the diagnosis of PCOS and rule out an ovarian tumor, a pelvic 
ultrasound should be ordered to investigate the presence of polycystic ovaries (figure I).1,3,7  
However, this test may not be very specific as over 20% of women without PCOS have this 
finding.  If all of the aforementioned disorders are ruled out and hyperandrogenism and chronic 
anovulation persist, PCOS should be diagnosed.1  In addition to the previous studies, a fasting 
lipid panel and a two-hour oral glucose tolerance test should be done to screen for dyslipidemias 
and diabetes or impaired fasting glucose.4   
Management of PCOS 
The management PCOS can be broken down into three categories: 1) correction of oligo-/ 
anovulation or irregular menses in association with infertility, 2) controlling symptoms of 
hyperandrogenism, and 3) management of the lifelong effects of insulin resistance.  This can be a 
difficult task due to the varying symptoms and emphasis placed on each symptom by individual 
women, in addition to the many treatment options available with lack of standardization.1 
Control of Irregular Menses and Anovulation in Women Not Attempting to Conceive 
Irregular menses can be very troublesome for women due to the variable start times.  Also, 
infrequent menses can cause more severe cramping and have heavier flow.1  Having irregular 
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menses can also be a great health risk for patients because it can put them at increased risk of 
endometrial cancer.  The lifetime risk of endometrial cancer is 2.6 percent in the general 
population, but in women with PCOS there is a 3-fold increase.1,7  They also tend to present 
earlier in life.  The increased risk of endometrial carcinoma results from prolonged periods of 
unopposed estrogen.  In women with chronic irregular menses, it is important to rule out 
endometrial carcinoma by biopsy.7  Four periods each year are needed to bring the increased risk 
of cancer into normal range.1  Oral contraceptives have been the standard treatment for irregular 
menses for several years and medroxyprogesterone acetate has been shown to decrease the risk 
of endometrial cancer.  Oral contraceptives work by suppressing androgen secretion by the 
ovaries and correcting unopposed estrogen.4,7  Oral contraceptives should not be used in women 
with a history of DVT or in women over 35 years old who smoke.  Birth control pills should also 
be used with caution in women with dyslipidemias, as they can worsen triglyceride levels.  
Women who are obese should lose weight as this can help to regulate menses.1,4   
Ovulation Restoration in Women Attempting to Conceive 
75 percent of anovulatory infertility is caused by PCOS, and women with PCOS can expect a 30-
50 percent first trimester miscarriage rate.  Management of infertility can be difficult for the 
clinician and upsetting to the patient.  Infertility management in PCOS is usually a team effort 
with physicians from endocrinology and obstetrics involved.1  Lifestyle changes and clomiphene 
are generally first line treatment.  If the first line treatment fails, then gonadotropins, insulin-
sensitizers and surgery are the next lines of management options.4 
 Lifestyle changes should be attempted first in any obese women with PCOS wanting to 
conceive.    Weight loss improves insulin resistance which plays a role in menstrual 
dysfunction.1  A loss in weight has been proven to restore ovulation in previously anovulatory 
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women.  One study by Kiddy et al. showed that with a weight loss of >5% resulted in about 40% 
of the studies participants became pregnant.9  Another study by Clark et al. resulted in a 90% 
ovulation rate in women with significant weight loss.  77.6% of those women who began 
ovulating conceived with 67% resulting in live births.10 
 Clomiphene citrate is often used when treating anovulation because of its proven 
effectiveness in inducing ovulation.  However, high doses are generally needed in obese patients 
and in high doses it can increase the risk of multiple gestations.1  Metformin and other insulin-
sensitizers, like the TZDs have also been proven to induce ovulation by improving insulin 
resistance2, but there has been some controversy as to whether they are as efficacious as 
clomiphene.  In small studies with insulin-sensitizers they have proven as efficacious as 
clomiphene, but other larger studies contradict these findings.11  Clomiphene has been studied 
with metformin at length and TZDs have been studied against placebo.  In a large randomized 
trial, Legro et al. found clomiphene to be superior to metformin or a combination of both in 
attaining pregnancy and live births as a primary outcome; however, the clomiphene group did 
result in more pregnancy related adverse events.  Also, metformin reduced insulin resistance in 
those afflicted women and did result in a considerable increase in pregnancy and live births.11  In 
a study by Cataldo et al. 55% of the participants reached ovulation while on rosiglitazone and 
those on the 8mg daily dose had an average 46% drop in insulinemia.12  Azziz et al. had similar 
results with troglitazone in a randomized, double-blind, placebo-controlled study.13  These 
results are consistent with other studies done with TZDs; however, troglitazone was taken off the 
market in 2000 due to hepatotoxicity.1  In those individuals who are clomiphene resistant, 
pretreatment with insulin-sensitizers improves outcomes of clomiphene and other fertility 
therapies.1,13 
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 When clomiphene and insulin-sensitizers fail, gonadotropins and surgical treatment are 
often used to induce ovulation.  About 20% of women with PCOS are clomiphene-resistant.14  
Laparoscopic ovarian diathermy or drilling is an alternative to gonadotropin therapy. 
Gonadotropin therapy involves daily injections of synthetic pituitary gland protein hormones, LH 
and FSH, in order to induce ovulation.14  The alternative, laparoscopic ovarian diathermy 
involves resecting portions of the ovaries to induce ovulation.  Many studies have shown that 
gonadotropin use and laparoscopic ovarian diathermy have similar efficacy.  Farquhar et al. 
found similar ovulation rates among women who underwent gonadotropin therapy versus 
ovarian drilling.  He also found that surgical therapy resulted in about one third lower than 
ovulation rates than gonadotropin therapy.  Gonadotropin therapy is also linked with increased 
risk of ovarian hyperstimulation which can be life threatening when severe and increased risk of 
multiple gestations.  Gonadotropin therapy is also very time consuming because most patients 
have a treatment course requiring injections nearly every day.  Laparoscopic surgery is more 
invasive, carries the small risk of infection and adhesions, and results in permanent, long-lasting 
effects on ovarian function.15  Ovarian surgery can also have beneficial long-term effects that 
gonadotropin therapy cannot mimic.  In a study by Mohiuddin et al. over half of the study’s 
participants had ongoing fertility and regular menstruation after the mean 100 month follow-up 
period.14 
Control of Hyperandrogenism Symptoms 
The hyperandrogen symptoms can be very disconcerting to women with PCOS and can present a 
challenge for clinicians when trying to reverse the effects.  Unfortunately, the treatments for 
hyperandrogenism are generally palliative instead of curative.4  The increase in androgens is 
likely due to an elevation in ovarian androgen secretion.  This results from an increase in insulin 
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stimulation of ovarian steroid-secreting cells, and also insulin-stimulated growth factors.  Most 
women present with hirsutism, acne, seborrhea or dandruff, and male pattern baldness.  
Hirsutism generally is the most common of these symptoms with about 60-83% of women with 
PCOS having some variety of the disease.6  The mainstay of treatment should be aimed at 
suppressing testosterone levels in the body or treating the source of the symptoms, as well as, 
treating the patients symptoms palliatively.3,4 
 Medical management of hyperandrogenism is aimed at reducing the amount of androgen 
systemically.  This is generally done with oral contraceptives and anti-androgens which include 
spironolactone, flutamide and finasteride.4  The anti-androgens all work in slightly different 
ways, but they all block the action of testosterone.  Oral contraceptives are often used in 
conjunction with an anti-androgen to produce a synergistic effect of androgen inhibition.  The 
anti-androgen drugs are contraindicated in pregnancy due to possible teratogenic effects.3 
 Hirsutism is generally treated with mechanical therapy.  Mechanical methods involve 
shaving, plucking, electrolysis, laser and hair removal creams.  Shaving is commonly used by 
women with little side effects, but can be undesirable for some women.  Plucking can lead to 
infections such as folliculitis and can be very difficult to pluck large areas of hair.  Electrolysis 
involves electrocoagulation of the hair follicle and is generally safe.  However, it may not be a 
permanent solution and can be unrealistic when dealing with a large area of hair.1,4   Laser 
therapy is aimed at damaging the hair follicle by thermal means.  Side effects include edema, 
erythema, blistering and temporary hyper-/hypopigmentation.  Laser treatment is more practical 
for large areas of hair removal.1   Lastly, Eflornithine hydrochloride 13.9% cream or Vaniqa is 
FDA approved for the treatment of hirsutism.4  Vaniqa slows, but does not stop the growth of 
hair.  Side effects are generally limited to skin irritation.  Unfortunately, Vaniqa is expensive and 
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not readily covered by most insurances, so its use is not wide spread.1  Metformin has also been 
proven efficacious when treating moderate to severe Hirsutism.  In a study by Harborne et al. 
women with PCOS and hirsutism were randomized to receive either metformin or dianette, an 
anti-androgen.  The study found that metformin was as effective as dianette at reducing hair at 
multiple anatomical sites.  However, compared with the dianette, metformin produced 
insignificant change in reducing androgen levels, but reduced insulin resistance significantly.6 
 The other symptoms of hyperandrogenism include acne, seborrhea and male pattern 
baldness.  Acne and seborrhea are generally treated as they would in individuals without PCOS 
with topical and oral antibiotics, and steroid creams, respectively.  Male pattern baldness can be 
treated with minoxidil or rogaine.  Rogaine is a vasodilator and has been proven to slow or stop 
hair loss while promoting hair growth.  Unfortunately, any measurable progress is generally lost 
within a few months of discontinuation of the drug.  In addition, women attempting to conceive 
should not use rogaine because it is a pregnancy category C drug.  It has been found to pass from 
mother to baby via breastmilk.16 
Management of Insulin Resistance 
Insulin resistance is perhaps the most important aspect of PCOS to manage because of the long-
term health risks that it poses, and the fact that it is either directly or indirectly related to the 
causes of many of the PCOS signs and symptoms.17  Most women with PCOS are also affected 
by some severity of insulin resistance, which puts them at an increased risk of cardiovascular 
events and underlying metabolic syndrome, and type 2 diabetes.  In women with PCOS and 
insulin resistance, most of them generally progress to type 2 diabetes.  The risk of type 2 diabetes 
is increased 4- to 7-fold compared with women in the general population, and they generally 
develop the disease earlier in life.  In addition, Dorkas et al. found that there was an 11-fold 
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increase in the risk of syndrome X (figure II).17, 18, 19  Women with PCOS have a 4-fold greater 
risk of being obese or morbidly obese.  They generally have lower HDL-C and higher 
triglycerides independent of BMI.19  All of these factors significantly increases the risk of 
morbidity and mortality from cardiovascular and diabetic complications for women with PCOS.  
Specifically, each factor is an independent risk for greater athersclerosis leading to elevated 
cardiovascular risk.18   
 Women with PCOS generally have elevations in predictors of future vascular disease 
including carotid wall thickness, CRP, homocysteine levels, and echocardiogram findings.19  In a 
case control study with 30, nonobese women, Orio et al found that carotid flow was significantly 
impeded in PCOS compared to controls.  The carotid wall thickness was measured by ultrasound 
and by flow-mediated dilation of brachial arteries.20  In another case control study, Orio et al. 
found increased cardiac size, left ventricular posterior wall thickness and greater end-systolic 
volume in PCOS patients.21  As mentioned above inflammatory markers like CRP and 
homocysteine have been recognized as vascular disease predictors.  In a study done by Boulman, 
36% of the PCOS women had a CRP of greater than 5 mg/L.  CRP levels greater than 2 mg/L are 
linked to increased risk for cardiovascular events.22  Schachter et al. found that women with 
PCOS had significantly higher levels of homocysteine in both obese and nonobese women.23  
Women with insulin resistance should be treated to not only decrease current symptoms, but in 
order to prevent degeneration to cardiovascular and diabetic complications. 
 When treating insulin resistance in women with PCOS, lifestyle changes should be first 
line therapy.  As mentioned before, weight loss can improve insulin resistance and is a very 
important factor in improving all PCOS symptoms.1  In a randomized study by Weinstock et al. 3 
groups of women either performed a trial of diet, diet and aerobic exercise, or diet and strength 
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training.  All groups had behavioral therapy.  All groups lost an average of 13.8 kg and had about 
a 61.8% drop in hyperinsulinemia.  There were no significant differences between diet and diet 
and exercise groups.24  Another study by Knowler et al compared metformin to moderate 
lifestyle changes in reducing the development of type 2 diabetes from insulin resistance.  During 
the 2.8 year follow-up period, metformin decreased the risk of developing type 2 diabetes by 
31% and the lifestyle change resulted in a risk reduction of 58%.25  Clearly, lifestyle 
modification is a very powerful and efficacious tool for clinicians to begin their PCOS therapy. 
 As mentioned before, metformin and TZDs also result in a reduction in insulin resistance 
and can be used to treat insulin resistance.3  Other prevention therapy should be targeted at 
specific symptoms of Syndrome X and should be treated with the same regimen as those 
individuals without PCOS.  Elevated blood pressure should be treated with diuretics, beta-
blockers,  calcium channel blockers, ACE-inhibitors and ARBs.  Dyslipidemias should be treated 
with statins, fibrates and other medications used to regulate lipids.19 
Discussion 
Polycystic Ovary Syndrome is a common disorder affecting women, but can be very difficult to 
diagnose and treat due to vague presenting symptoms and a lack of standardization in treatment.  
PCOS is defined as having oligo- or anovulation and hyperadrogenism in the absence of other 
disorders that may cause these symptoms.  Disorders that need to be ruled out include: 
pregnancy, hypothyroidism, hyperprolactinemia, late onset congenital adrenal hyperplasia, 
androgen secreting tumors, hyperthecosis, adrenal or pituitary tumor, cushings syndrome, 
acromegaly, primary ovarian failure and an insulinoma.1,3,4    
 Women with PCOS may have varying symptoms and signs, as well as, different priorities 
placed on reversing certain symptoms.  Therapy should be appropriate for each patient taking 
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into consideration her fertility, health and cosmetic desires.  Generally, there are three main 
groups to identify and treat when managing an individual with PCOS: management of 
anovulation and infertility, controlling symptoms of hyperandrogenism and treating insulin 
resistance and any related problems.  All groups should first be treated with lifestyle changes as 
this can yield improvement in all areas.  Diet, exercise and weight loss has proved efficacious in 
restoring ovulation, improving hyperandrogenism and decreasing insulin resistance.  
Management of anovulation and infertility will depend on whether or not the patient is 
attempting to conceive.  If not, then oral contraceptives to decrease the risk of endometrial 
carcinoma will be the appropriate choice.1  If the individual is trying to conceive, then 
clomiphene citrate is considered first line in order to restore ovulation and promote fertility.  If 
the patient is clomiphene resistant then, metformin should be tried as it has shown to improve 
ovulation although not as well as clomiphene.11  The next options include laparoscopic ovarian 
diathermy or gonadotropin therapy.  Both options come with their risks and benefits and a 
decision will be based on the clinician’s recommendations and the patient’s choice.   
 When treating symptoms of hyperandrogenism such as: hirsutism, acne, seborrhea and 
male pattern baldness, anti-androgens should be used in all patients not attempting to conceive in 
order to reduce the amount of systemic testosterone causing the symptoms.  Specifically, 
hirsutism is generally treated with mechanical methods like: shaving, plucking, laser, electrolysis 
and Vaniqa.  Metformin has also shown to help improve hirsutism.6  Acne can be treated with 
topical and oral antibiotics and seborrhea can be managed with steroid creams.  Rogaine should 
be used in women with male pattern baldness; however, must be avoided in women who are 
pregnant, breastfeeding or attempting to conceive.  
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 Finally, and most importantly, women with PCOS should always be screened and treated 
for insulin resistance and syndrome X to prevent and slow the progression of diabetic and 
cardiovascular complications.  If insulin resistance is found, patients should be put on metformin 
or TZDs to increase insulin sensitization.  Also, if other disorders associated with metabolic 
syndrome are present, such as hyperlipidemia or hypertension, they should be treated 
appropriately.18  Figure III gives an overview of PCOS management. 
 Future study ideas include more studies on the affect of lifestyle changes on all symptoms 
of PCOS and whether or not treating insulin resistance early results in a significant change in 
future morbidity and mortality.  In addition, further research to establish standard diagnostic 
criteria and treatment should be addressed.  PCOS is a treatable condition that warrants proper 
workup in women in whom it is suspected.  If women with this disorder are diagnosed and 
managed properly with lifestyle changes and other pharmacological and surgical therapy, most 
distressing symptoms can be alleviated and future complications of diabetes and cardiovascular 
events can be slowed or prevented.    
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Table I: Etiology Hypotheses of Polycystic Ovarian Syndrome 
Hypothalamic-pituitary communication abnormalities cause abnormal secretion of 
gonadotropin releasing hormone and luteinizing hormone, causing increased ovarian 
androgen production. 
Enzymatic defect of ovarian steroidogenesis favoring excess androgen production. 
 Insulin resistance leads to metabolic and reproductive abnormalities in PCOS. 
Information for Table I derived from reference 5 
 
 
Table II: Symptoms and Signs of Polycystic Ovarian Syndrome 
Oligomenorrhea/Amenorrhea Hirsutism 
Oligo-/Anovulation and Infertility Acne 
Chronic First Trimester Miscarriage Acanthosis Nigricans 
Obesity with high rate of centripetal fat 
distribution 
Male Pattern Baldness 
Sleep Apnea Enlarged Ovaries 
Information for Table II derived from reference 1 and 4 
 
 
Table III: Differential Diagnosis for PCOS and Associated Laboratory Tests and Values 
Diagnosis Laboratory Test Normal Value 
Pregnancy Urine or Blood HCG Positive 
Hypothyroidism TSH 0.4-4 microunits/ml 
Hyperprolactinemia Prolactin <20ng/ml 
Late onset congenital 
adrenal hyperplasia 
17-hydroxyprogesterone <200 ng/dl in follicular 
phase 
Ovarian or other androgen 
secreting tumor 
Total Testosterone 24-47ng/dl 
Hyperthecosis Total testosterone 24-47ng/dl 
Adrenal Tumor DHEA-S 12-535 mcg/dl 
Cushings Syndrome 24-hr urine free cortisol 23-195 mcg/24 hr 
Acromegaly IGF1 10-1000 ng/ml 
Pituitary Tumor LH/FSH ratio < 2.0 
Primary Ovarian Failure LH/FSH ratio < 2.0 
Insulinoma Insulin 
C-Peptide 
Proinsulin 
5-20 microunits/ml 
<3.3-5ng/ml, age dependent 
<0.8 ng/ml 
Information for Table III derived from reference 1, 3, and 4 
 
 
  22 
  
Figure I: Examples of Polycystic Ovaries; a) Ultrasound view, b) Gross view 
Figure I: a) picture from reference 8, b) picture from reference 9 
 
 
 
Figure II: Age-adjusted prevalence of metabolic syndrome criteria in women with PCOS 
From reference 18 
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PCOS Management Oligo-/Anovulation 
Hyperandrogenism 
Insulin Resistance & 
Syndrome X 
Attempting 
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Oral 
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Citrate 
Metformin 
Laparoscopic 
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Therapy 
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indicated 
Hirsutism Acne 
Male Pattern 
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Rogaine Steroid 
Creams 
Mechanical: 
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Laser,  Electrolysis 
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Metformin 
OTC 
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Topical & 
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Figure III: An Overview of PCOS Management 
Information from references 1, 3, 14, 16, 18 
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